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tual equivalence to ‘hassled’. CONCLUSIONS: Though not always possible to
translate an English word exactly into the target language, a full translation and
linguistic validation process, including creation of a concept elaboration document
followed by an in-depth discussion at back-translation review stage, enables a
conceptually equivalent translation to be found. The concept elaboration docu-
ment should, where possible, be created in conjunction with the instrument de-
veloper.
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BACKGROUND: Incremental cost-effectiveness ratios (ICERs) are used to report the
results of cost-effectiveness (CE) analyses and represent the cost per unit of effec-
tiveness of a more costly and more effective option. However, numerous concep-
tual and practical problems limit the usefulness of ICERs for decision making.
These problems include, but are not limited to, negative ICERs, one-way sensitivity
analyses, complexity of multiple comparator analyses, and statistical limitations
with ratios. The net benefits approach was developed to address the statistical
limitations of ICERs and is now an accepted methodology used in probabilistic
sensitivity analysis to estimate CE confidence intervals and plot acceptability
curves. However, despite the remaining challenges and limitations the use of ICERs
persists, raising the question: Is it time to eliminate the use of ICERs in the report-
ing of CE analyses? METHODS: We propose expanding the net benefit method to
present deterministic CE analysis results using a net monetary benefit (NMB) chart
or table. ANMB chart is plottedwith the x-axis representing theWTP threshold and
the y-axis representing the NMB. The NMB of each option is a line with the inter-
cept representing the cost and the slope representing the effectiveness across a
specified range of WTP values. The line with the greatest NMB at a given WTP
represents the most cost-effective option at that WTP. The vertical distance be-
tween two lines represents the incremental NMB. Dominance, extended domi-
nance, and the frontier are captured graphically and intuitively. Multiple compar-
ator analyses are simplified and one-way sensitivity analyses are enhanced due to
the elimination of negative ICERs. CONCLUSIONS: A net benefits approach pro-
vides a more intuitive, informative, and useful method to present CE results than
the use of ICERs. Moreover, it has the benefit of facilitating a uniform and consis-
tent approach to presenting the results of deterministic and probabilistic CE anal-
yses.
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In randomized crossover designs, intraclass correlation coefficients (ICCs) are often
used to assess the concordance between scores on different administration ver-
sions of patient-reported outcome (PRO) measures. An ICC and its associated cri-
terion for “adequate” concordance enable analysts to simplify information and
provide researchers with a quick and easy way to interpret analysis output. This
strength of the ICC—its simplicity—may also be a weakness. Analysts may over-
look important information (e.g., biases, outliers) when ICCs are used as the pri-
mary method for assessing concordance. One way to avoid overlooking important
information is to include the evaluation of Bland-Altman plots when assessing
concordance. Bland-Altman plots allow one to visually determine whether two
measures produce similar scores, therefore, supplementing the concordance in-
formation gained from the ICC evaluation. ICCs and Bland-Altman plots comple-
ment each other’s strengths. ICCs provide an efficient and concise estimate to
determine the comparability of versions, while Bland-Altman plots provide a
greater level of detail that incorporates a broader view of the analyzed distribu-
tions. The use of the two methods together provides a more holistic view of con-
cordance. We present Bland-Altman plots and corresponding ICCs under a ran-
domized crossover-design, using the Lung Function Questionnaire, a PRO
instrument originally designed to be administered via paper, and later via three
alternate administration versions (Web, interactive voice response system, and
interview). We provide examples to illustrate instances in which ICCs and Bland-
Altman plots agree and disagree. GSK study number: ADC001HO.
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OBJECTIVES: The differences in the active substance of biosimilars compared to
their originator reference product can cause risks that are unique to biologics,
mainly: immunogenicity, long-term safety risks, and lack of efficacy. These risks
are unknown at the launch of a biosimilar and can lead to unexpected costs for
payers. The aim of this abstract is to describe a methodology for evaluating the
unknown risks of biosimilars. METHODS: A structured literature review revealed
that for many biologics, post-marketing observational studies have been set up to
identify long-term safety and efficacy outcomes. These studies are a useful source
of information to quantify the unknown risks of biosimilars and definemethods of
minimizing those risks. The information required is product- and population-spe-
cific. This information first includes potential safety issues such as immunogenic-
ity (all biologics), serious infections and autoimmune disorders (anti-TNFs, inter-
ferons), and increased mortality and cardiovascular events (epoetin). Second,
information is available on long-term benefits such as clinical outcomes that im-
prove overall survival (e.g. reduced recurrence of malignancies through interferon
use and reduced cardiovascular events through insulin use), reduction in health-
care resource utilization (epoetin, somatropin), and proportion of long-term re-
sponders (figrastim, anti-TNF, somatropin). Finally, observational data can be used
to optimize treatment regimens to achieve maximum treatment benefit (epoetin,
insulin, somatropin). All these data can be used in an economic evaluation where
the unknown risks for biosimilars are quantified through worst- and best-case
scenarios. CONCLUSIONS: Often, payers are attracted to biosimilars that have the
lowest acquisition costs. However, the risks of unknown information for these
biosimilars should be valued against the lower price of these drugs. Observational
data for the originator biologic product can be leveraged to quantify these risks.
This can help determine for which drugs and for which populations the unknown
risks outweigh the reduction in acquisition costs.
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OBJECTIVES: The translation of PRO measures requires a rigorous procedure, in-
cluding dual forward translations, reconciliation, back translation and review, and
debriefing interviews. The relevance of including blinded back translations has
been widely discussed; however, there has been little discussion around back
translation methods. This research aims to gauge the importance of having two
back translations versus only one.METHODS: Past translation and linguistic vali-
dation projects employing the procedures outlined above were reviewed to com-
pare the methodology of using one back translation versus two. RESULTS: In the
dual-back projects, numerous instances were found in which only one back trans-
lator detected an issue. For example: 1. Simple mistranslations can be revealed by
one translator but not another; e.g. ‘activities at home’ was back translated verba-
tim by one back translator but as ‘household activities’ by another, revealing that
the translated term was too narrow and related only to chores; 2. Similarly, con-
textual mistranslations may become apparent in dual back translations. In one
ePRO script, ‘enter training module’ meant to click through to the next page. One
back translator wrote ‘enter’, while ‘insert’ in the second translation highlighted
that the wrong term had been used in this context; 3. Dual translations are also
useful for elucidating nuances in meaning. In Danish, the phrase ‘bad tempered’
became ‘lose my temper’ in one back translation, allowing the lead translator to
alter the ambiguous translation; 4. Dual meanings in the target language may also
be highlighted, for example in Gujarati ‘hospitalisations’ was correctly back trans-
lated by one translator, but the other translated it as ‘clinic’, showing an ambiguity
in the translation. CONCLUSIONS: The high proportion of issues highlighted by
only one back translator, show the importance of using two blinded back transla-
tors in the translation of PRO measures.
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The ISPOR Principles of Good Practice paper on the translation of patient-reported
outcome (PRO) measures includes cognitive debriefing as a key step in the trans-
lation process. Cognitive debriefing refers to the process of asking patients to de-
scribe to an interviewer what each question/instruction means to them in their
own words. This allows experienced project managers to then determine whether
the patient has correctly understood the conceptual meaning of the question/
instruction and therefore, by implication, whether the translation is accurate. De-
spite the FDA guidelines emphasising the importance of assessing the content
validity of PRO translations, cognitive debriefing is not always feasible or ethically
acceptable with certain patient groups. These groups include children, severely ill
patients and patients with mental health problems, for whom prolonged inter-
views could cause distress. In these circumstances, alternative methodologies
should be employed to establish whether the wording is suitable for the given
population. Evidence from working with such patients indicates that clinician re-
views, caregiver reviews and assessments of language complexity and suitability
are all useful alternative methods for establishing the acceptability of PRO trans-
lations for particular patient populations. Two examples include pilot testingmen-
tal health measures with clinicians as a substitute for patients experiencing acute
symptoms and pilot testing paediatric measures with health practitioners and
teachers working with children from the target age group. Cognitive debriefing is a
useful tool in the translation and linguistic validation of PROmeasures but a more
flexible approach is required to ensure that certain patients are not unduly dis-
tressed and burdened by the process.
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Meta-analysis involves pooling effect sizes to combine results from studies at-
tempting to answer similar research questions. Typically, a commonmetric is used
to estimate associations between independent and dependent variables in pooled
studies. Nonetheless, studies vary considerably in their measurement of effect
sizes as well as the nature of studied variables. The calculation of an effect size r
allows the pooling of results that are reported in a variety of forms. In the presence
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